Kohlberg Kravis Roberts is a prominent global investment firm that specializes in managing a diverse range of alternative asset classes, including private equity, energy, infrastructure, real estate, and credit, as well as hedge funds through strategic partnerships. Founded in 1976, the firm focuses on generating attractive investment returns by employing a disciplined and patient investment approach. KKR is committed to driving growth and value creation in its portfolio companies while aligning its interests with those of its investment partners. The firm also provides comprehensive human resources services to enhance operational effectiveness. With a presence in multiple countries, including India and Japan, KKR continues to leverage its extensive expertise and industry knowledge to deliver value across its investment strategies.
9 West 57th Street, Suite 4200, New York, New York 10019, US
Taski Ahmed
Principal, KKR Prisma
Mustapha Angwa
CEO
Anne Arlinghaus
Managing Director
Joe Bae
Co-President and Co-COO
David Biener
VP Finance
Todd Builione
Member, President of KKR Credit
Jim Burns
Partner
Daniel Celeghin
Managing Director, Client and Partner Group
Spencer Chavez
Principal
Mukul Chawla
Partner, Head of Asia Pacific Growth Equity
Steve Codispoti
Director, Finance
Benjamin Conner
Managing Director
Kendra Decious
Director, Finance
Patrick Devine
Director
Brian Dillard
Partner and Head of Asia Credit
Brandon Donnenfeld
Director
Jamison Ely
Director
Mark Ennis
Director
Len Fliegel
Director
Marco Fontana
Managing Director
Brandon Freiman
Partner, Head of North American Infrastructure
Philipp Freise
Co-Head of European Private Equity
Terence Gallagher
Managing Director
Travers Garvin
Director, Public Affairs
Felix Gernburd
Managing Director
Alan Grant
Principal, KKR Capstone
Elizabeth Hammond
Managing Director
Chris Harrington
Partner
Erich Heintzen
Director
Jill Henn
Managing Director, Human Capital
Sota Horiuchi
Principal, Private Equity
Jeff Van Horn
Managing Director, Credit
Paul Horwood
CFO, European Operations
Mark Hunt
Director, Capital Management Group
Johannes P. Huth
Managing Director and Head of KKR EMEA
Hisao Iijima
Principal, Private Equity
Gary H. Jacobs
Managing Director, Capital Management Group
Zhen Ji
Managing Director, China
Franziska Kayser
Managing Director
Kazuyuki Kido
Managing Director
Philip Kim
Managing Director
Thomas Kim
Managing Director and Global Risk Manager
Daan Knottenbelt
Partner
Rie Koike
Principal, Client and Partner Group
Joan Lacagnina
Managing Director, Finance
Jeremiah Lane
Principal
Dashiell Lane
Director, Energy and Infrastructure
David Lang
Partner
Joshua Lederman
Principal and Associate
Elissa Leechawengwongs
Principal, Private Equity
Vincent Letteri
Managing Director, TMT Growth Equity
Robert Lewin
Partner
Xiang Li
Managing Director, Private Equity
Frances Lim
Managing Director, Global Macro and Asset Allocation and Portfolio Mgt of Strategic Partnerships
Max Lin
Partner and Director, Private Equity
Lucy Liu
Director, Client and Partner Group
Ming Lu
Partner and Co-Head of Asia Private Equity Business
Rony Ma
Director
Blaine MacDougald
Director and Co-head of Credit Research, Credit
Emily Mason
Principal, KKR Prisma
Kyle Matter
Director
Patrick Mattson
Managing Director
Kevin McMahon
Managing Director
Hilary McNamara
Director, Business Operations
David McNellis
Managing Director, Global Macro and Asset Allocation
Henry McVey
Partner and Head of Global Macro and Asset Allocation, CIO of KKR Balance Sheet
Ken Mehlman
Partner and Global Head of Public Affairs; Co-head KKR Global Impact
Jimmy Miele
Principal
George Mueller
Managing Director
Katherine T. B. de Mul
Director, Operations and Client Services
Narender Nanchary
Principal, Hedge Funds
Sanjay Nayar
CEO
William Needham
Managing Director
Sean Nelson
Director
Lesley Nurse
Director, Client and Partner Group
Scott Nuttall
Co-CEO
Ted Oberwager
Principal, Private Equity
Christian Ollig
Director, Private Equity
Timotheus Osnabrug
Director, Private Equity
John Park
Director, Private Equity
Chung Ho Park
Director, Private Equity
Vishal Patel
Managing Director
Clayton Perry
Managing Director, Client and Partner Group
Daniel Pietrzak
Partner
Samuel Plotner
Director
Jaka Prasetya
Partner
Sharath Reddy
Director, Credit
John Reed
Director, Credit
Janice Cook Roberts
Director, Client and Partner Group
Paul Roberts
Managing Director, KKR Prisma
James Rudy
Director, Principal Activities
Jean -Pierre Saad
Director, Private Equity
Matt Salem
Partner and Head of RE Credit
Kaveh Samie
Managing Director, Client and Partner Group
Richard Sarnoff
Managing Director
Kugan Sathiyanandarajah
Managing Director and Head of Healthcare Strategic Growth in Europe
Jeffrey Schachter
Managing Director
Lucian Schönefelder
Partner
Vance Serchuk
Managing Director, Americas Private Equity, Industrials Team
Stephen Shanley
Partner
Peggy Shaughnessy
Managing Director, Business Operations
Blake Shorthouse
Managing Director
Rob Siegel
Director, Information Technology
Tashwinder Singh
Director, Capital Markets
Duncan Smith
Principal, Credit
Pete Stavros
Co-Head of Global Private Equity
Chris Sun
Partner, Private Equity
Karan Swani
Director, Private Equity
Marta Szczerba
Director
Waldemar Szlezak
Managing Director
Weiyu Tan
Managing Director
Nate Taylor
Co-Head of Americas Private Equity
Paige Thacher
Principal
Cade Thompson
Partner, Capital Markets
Gaurav Trehan
Head of Asia Private Equity
Cecilio Velasco
Managing Director
Steven Wang
Principal, Private Equity
Douglas Watt
Managing Director
Joshua T. Weisenbeck
Partner
Dave Welsh
Partner and Head of Technology Growth Equity
Ryan L.G. Wilson
Managing Director
Alisa A. Wood
Partner
Angela Yang
Principal, Credit
Annie Yangeksakul
Principal, Hedge Funds
Eiji Yatagawa
Partner
Past deals in Health Diagnostics
HealthCare Global Enterprises
Acquisition in 2025
HealthCare Global Enterprises is a cancer center is a center which offers complete diagnosis and treatment radiation, surgical and medical oncology services under one a single roof. cancer care services. The also operate fertility clinics, multi-specialty hospitals providing cardiology, neurology, orthopedics, gastroenterology, urology, pulmonary and critical care services. Its service offerings comprise of the clinical lab, diagnosis, robotic surgery, bone marrow transplantation, and radiation oncology.
HealthCare Global
Acquisition in 2025
HealthCare Global they focuses on cancer care, tertiary care, infertility treatment, advanced screening, and diagnostics.
Henry Schein
Post in 2025
Henry Schein is a leading provider of healthcare products and services, primarily catering to office-based dental, medical, and animal health practitioners. The company operates through two main segments: healthcare distribution and technology & value-added services. In its healthcare distribution segment, Henry Schein combines global dental and medical businesses to distribute a wide range of consumable products, small equipment, laboratory supplies, and vitamins. The technology and value-added services segment focuses on offering practice management software and other technological solutions that enhance operational efficiency for healthcare professionals. With a strong emphasis on leveraging a network of people and technology, Henry Schein aims to support practitioners in delivering high-quality care.
Immedica
Acquisition in 2024
Immedica is a fast-growing private niche pharma group. Its headquarter is based in Stockholm, Sweden, and it has commercial coverage across Europe and the Middle East. Immedica provides significant know-how and experience from the commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access to specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality, and product distribution. Immedica’s main owner is Impilo AB, a private Nordic investment company established in 2017, with more than SEK 3.6 billion in committed capital from leading Nordic and international investors.
Cortex
Private Equity Round in 2023
Cortex is creating an innovative, totally integrated, all-encompassing platform for assessing and treating AFib with precision, simplicity, and speed. The company has formed a proficient team comprising highly skilled and experienced engineers and clinical experts dedicated to introducing this innovative suite of technologies to the market.
Clinisupplies
Acquisition in 2022
Clinisupplies is a manufacturer and supplier of medical supplies focused on managing both acute and chronic conditions. The company's product range includes intermittent catheters, urinary sheaths, tubular support bandages, catheter valves, surgical tape, triangular bandages, and drainage bags. In addition to these medical supplies, Clinisupplies provides Clinidirect home delivery and clinical nursing services, which include drop-in clinics and home visits. Their nurses collaborate with NHS professionals to offer guidance on products, clinical education and training, and management of community spending, ensuring that patients receive comprehensive care and support.
Digital Diagnostics
Series B in 2022
Digital Diagnostics Inc. is an artificial intelligence diagnostics company focused on enhancing the quality, accessibility, and affordability of healthcare through advanced technology. Founded in 2010 in Coralville, Iowa, by Michael Abramoff, the company has developed a range of autonomous algorithms that analyze medical images to detect various diseases. Its flagship products include IDx-DR for diabetic retinopathy, IDx-G for glaucoma indicators, and IDx-AMD for age-related macular degeneration. Additionally, Digital Diagnostics provides algorithms for detecting other conditions such as Alzheimer's disease and cardiovascular risks. By eliminating the diagnostic burden from specialists, the company's AI platform aims to establish a new standard of care, democratizing healthcare and improving patient outcomes. The company collaborates with patient advocacy groups and regulatory bodies to facilitate the adoption of its innovative solutions both in the United States and internationally.
Clarify Health Solutions
Series D in 2022
Clarify Health Solutions, Inc. operates a data-driven platform designed to enhance patient care by facilitating real-time engagement among patients, clinicians, and care teams. The platform, known as Clarify Episode, utilizes real-time data to optimize care workflows, stratify patients based on various characteristics, and identify potential complications early on. Key components of the platform include Care Pilot, which empowers patients in their healthcare journey; Care Connect, which allows clinicians to monitor and intervene as needed; and Care Prism, which provides management with essential business analytics. By leveraging machine learning and data analytics, Clarify Health offers solutions that improve transparency, personalization, and engagement for patients while streamlining tasks for healthcare professionals. The company, founded in 2015 and based in San Francisco, has formed a strategic alliance with Leidos to further enhance its offerings.
Brightline
Series C in 2022
Brightline, Inc. is a provider of pediatric behavioral health care services, established in 2019 and headquartered in Palo Alto, California. The company offers a range of services including behavior therapy, psychiatry and medication support, speech-language therapy, and occupational therapy. Brightline operates as a technology-enabled behavioral health home, utilizing innovative technology and virtual services to deliver integrated care. Its collaborative care team focuses on supporting children throughout their developmental stages and addressing the needs of their families. Brightline was previously known as Emilio Health, Inc. and rebranded in May 2020.
Biosynth
Acquisition in 2021
Biosynth is a custom synthesis and manufacturing services company that aims to streamline the fragmented supply chain in the pharmaceutical and diagnostics sectors. By enhancing the availability of complex chemicals, peptides, and biological materials, Biosynth increases the productivity of its clients, facilitating faster development and market introduction of new therapies and diagnostic assays. The company offers a comprehensive range of products, including carbohydrates, nucleosides, enzyme substrates, and natural products, as well as a research product catalog featuring over one million items to support research and development efforts. With global research, manufacturing, and distribution facilities, Biosynth caters to the needs of diagnostic and pharmaceutical companies, ensuring they have access to essential materials for their product development.
Sapphiros
Series A in 2021
Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.
Paige
Series C in 2021
Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.
Clinisupplies
Acquisition in 2020
Clinisupplies is a manufacturer and supplier of medical supplies focused on managing both acute and chronic conditions. The company's product range includes intermittent catheters, urinary sheaths, tubular support bandages, catheter valves, surgical tape, triangular bandages, and drainage bags. In addition to these medical supplies, Clinisupplies provides Clinidirect home delivery and clinical nursing services, which include drop-in clinics and home visits. Their nurses collaborate with NHS professionals to offer guidance on products, clinical education and training, and management of community spending, ensuring that patients receive comprehensive care and support.
ELSAN
Acquisition in 2020
ELSAN provides medical services. The Company offers cancer treatment, obstetrics, pediatrics, and cardiology, as well as diagnosis, follow up care, and surgical services. Vedici serves patients and medical professionals throughout France.
Univercells
Venture Round in 2020
Univercells is a provider of biomanufacturing solutions focused on making biologics, including vaccines and therapeutics, more accessible and affordable. The company offers innovative technologies designed to reduce manufacturing costs significantly, achieving up to 90% savings on the cost of goods and over 75% in capital investment. Their approach utilizes single-use technologies and integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode. Univercells also provides a range of biomanufacturing services, including scale-X hydro, scale-X carbo, and NevoLine, along with integrated support such as equipment confirmation, facility design, and bioprocess excellence. This comprehensive offering aids cell and gene therapy manufacturers in scaling their operations from research and development to commercial production, ultimately addressing global health challenges.
BrightSpring Health Services
Acquisition in 2019
BrightSpring Health Services is a comprehensive healthcare platform that offers a range of clinical, nonclinical, pharmacy, and ancillary care services tailored for individuals across various ages and health conditions. As one of the largest providers of home and community-based health services, BrightSpring specializes in serving complex and high-cost populations. Its primary offerings include behavioral health services, such as autism support, home health care encompassing personal care, hospice, and neuro therapy, as well as job placement and vocational training. The company also utilizes pharmacy solutions and telecare technologies to enhance its service delivery, focusing on patients covered by Medicare, Medicaid, and commercial insurance. The majority of its revenue is derived from its Pharmacy Solutions segment, underscoring its commitment to integrated care for diverse patient needs.
Hetian Group
Acquisition in 2018
HeTian is a professional hospital management company specialized in operating and investing in integrated health care service providers. HeTian currently operates seven award-winning hospitals and health care centers focused on underserved Chinese cities. The company’s vision is to improve access to quality health care services by building a network of primary medical care providers supported by modern health care management best practices.
Clarify Health Solutions
Series B in 2018
Clarify Health Solutions, Inc. operates a data-driven platform designed to enhance patient care by facilitating real-time engagement among patients, clinicians, and care teams. The platform, known as Clarify Episode, utilizes real-time data to optimize care workflows, stratify patients based on various characteristics, and identify potential complications early on. Key components of the platform include Care Pilot, which empowers patients in their healthcare journey; Care Connect, which allows clinicians to monitor and intervene as needed; and Care Prism, which provides management with essential business analytics. By leveraging machine learning and data analytics, Clarify Health offers solutions that improve transparency, personalization, and engagement for patients while streamlining tasks for healthcare professionals. The company, founded in 2015 and based in San Francisco, has formed a strategic alliance with Leidos to further enhance its offerings.
Envision Healthcare
Acquisition in 2018
Envision Healthcare is a provider of physician-led, outsourced medical services that offers a comprehensive range of healthcare solutions. The company serves consumers, hospitals, healthcare systems, health plans, and government entities at various levels. Its services span the continuum of care, including medical transportation, ambulatory surgery, home health services, clinical solutions, and post-acute patient care. By focusing on coordinated, clinically-based care, Envision Healthcare aims to enhance the patient experience while also working to reduce overall healthcare costs.
Angelica Corp
Acquisition in 2017
Angelica Corporation is the provider of textile rental and linen management services to the U.S. healthcare market. The organization provides laundry and linen management services to hospitals, long term care facilities, and out-patient medical practices from 26 service centers across the nation.
Apollo Hospitals
Post in 2013
Apollo Hospitals is widely recognized as the pioneer of private healthcare in India, and was the country’s first corporate hospital. The Apollo Hospitals Group, which started as a 150-bed hospital and today, operates 9200 beds across 64 hospitals. A forerunner in integrated healthcare, Apollo has a robust presence across the healthcare spectrum. The Group has emerged as the foremost integrated healthcare provider in Asia, with mature group companies that specialize in insurance, pharmacy, consultancy, clinics and many such key touch points of the ecosystem. The Apollo Group has touched the lives of over 45 million patients, from 121 countries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.